---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000072"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:00:42.861749+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025

## Summary
- Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.
- R&D expense $7.8M, G&A $3.0M; cash and equivalents $18.4M at March 31, 2025.
- DFS event-driven interim analysis of Phase 2 AMPLIFY-7P trial (ELI-002 in PDAC) expected in Q3 2025.
- FDA alignment on key design elements of planned Phase 3 study for ELI-002 in resected mKRAS PDAC.
- Appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer in March 2025.

## SEC filing metadata
- accession: 0001601485-25-000072
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/0001601485-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/angn-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000072
- JSON: https://secwatch.observer/filing/0001601485-25-000072.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.